In an effort to keep our shareholders and analysts informed and up to date on the progress of our promising R&D programs, we are launching Teva In-Focus .
This new webinar series provides an in-depth view of Teva’s R&D strategies and progress in primary therapeutic areas in a format that is focused, detailed, and accessible.
Teva In-Focus kicks off on Tuesday, October 8 th at 8:00am Eastern Time with a focus on our Respiratory franchise, providing insight into Teva’s commercial and R&D franchise as well as our strategy for building a leadership position in respiratory therapies.
Teva In-Focus will include a review of the global market and unmet needs, our approach to innovation and therapeutic development, and a deep dive into key projects that we believe will drive Teva’s future growth in the respiratory market.Dr. Michael Hayden, Teva’s President of Global R&D and Chief Scientific Officer, will lead the webinar and will be joined by Teva’s respiratory franchise leadership including Hans Luijendijk, Head of Global Respiratory Marketing, Global Specialty Medicine Group and Dr. Tushar Shah, Global Respiratory R&D, Teva Global R&D. A question and answer session will follow the presentation.
|Webinar access details:|
|Meeting Title:||Teva Respiratory Webinar|
|Meeting Date:||October 08, 2013|
|Meeting Time:||08:00 AM [Eastern Time]|
|Duration:||1 Hour 30 Minutes|
|1 (800) 303-0442||US Toll Free|
|1 (847) 413-3733||International|
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV